<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35478359</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Regulatory Approval in ALS; When Is a Single Study Enough?</ArticleTitle><Pagination><StartPage>737</StartPage><EndPage>739</EndPage><MedlinePgn>737-739</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26371</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-7075-1681</Identifier><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Centers for ALS Mass General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Barrow Neurological Institute, Phoenix, AZ.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>5</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35478359</ArticleId><ArticleId IdType="doi">10.1002/ana.26371</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve 2021;63:31-39.</Citation></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium Phenylbutyrate-Taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 2020;383:919-930.</Citation></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505-512.</Citation></Reference><Reference><Citation>Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013;12:1059-1067.</Citation></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, et al. The combined assessment of function and survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:162-168.</Citation></Reference><Reference><Citation>van Eijk RP, Eijkemans MJ, Rizopoulos D, et al. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol 2018;10:333-341.</Citation></Reference><Reference><Citation>Oeckl P, Jardel C, Salachas F, et al. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:404-413.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>